Latest / DDReg Knowledge Capsule / Global Orphan Drug Designations: Building a Cross-Market Strategy

Transcript

Global Orphan Drug Designations: Building a Cross-Market Strategy · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to ded acknowledged capsule. I want you to imagine
• 0:03
  Speaker 1: just for a second, that you are a brilliant medical researcher.
• 0:07
  Speaker 1: You know, you've spent a decade in the lab, and
• 0:09
  Speaker 1: you've finally done.
• 0:10
  Speaker 2: It, the ultimate Eureka moment.
• 0:11
  Speaker 1: Exactly, you have discovered a genuine life altering breakthrough for
• 0:17
  Speaker 1: a terrible, debilitating disease. It is, by all accounts, a
• 0:22
  Speaker 1: true medical miracle. But and here is the massive catch
• 0:27
  Speaker 1: this disease. It only affects about five thousand people on
• 0:30
  Speaker 1: the entire planet.
• 0:31
  Speaker 2: Yeah, that's incredibly rare.
• 0:33
  Speaker 1: Right, So you have this incredible, proven science sitting in
• 0:36
  Speaker 1: a test tube, but how on earth do you actually
• 0:39
  Speaker 1: afford to bring it to the pharmacy shelf.
• 0:41
  Speaker 2: It's a devastating scenario, honestly, and historically it represented this
• 0:45
  Speaker 2: just well, a permanent brick wall for modern.
• 0:47
  Speaker 1: Medicine because the math just doesn't work, doesn't.
• 0:50
  Speaker 2: The underlying problem is that the research and development cost
• 0:52
  Speaker 2: to prove a drug is safe and effective. I mean
• 0:55
  Speaker 2: we're talking massive multi phase clinical trials, specialized manufacturing, thousands
• 1:00
  Speaker 2: of hours of regulatory.
• 1:01
  Speaker 1: Reviews, which costs hundreds of millions of.
• 1:04
  Speaker 2: Dollars easily, and those base costs are practically identical. Whether
• 1:09
  Speaker 2: your drug is destined to treat fifty million people or
• 1:12
  Speaker 2: you know, fifty people.
• 1:13
  Speaker 1: You would literally bankrupt your company trying to save those
• 1:16
  Speaker 1: five thousand people and that economic paradox. That's our mission
• 1:19
  Speaker 1: for today's deep dive. We are unpacking a really comprehensive
• 1:23
  Speaker 1: strategy framework developed by DDRI reg Pharma.
• 1:26
  Speaker 2: It was a fascinating look at the industry it really is.
• 1:29
  Speaker 1: It focuses on how developers navigate the complex global maze
• 1:33
  Speaker 1: of what are called orphan drug incentives. We're going to
• 1:36
  Speaker 1: explore how pharmaceutical companies strategically piece together all these different
• 1:40
  Speaker 1: international regulations to make developing rare disease treatments economically viable.
• 1:46
  Speaker 2: And zooming out for a second, it's important to remember
• 1:48
  Speaker 2: that rare diseases collectively affect hundreds of millions of people worldwide.
• 1:53
  Speaker 1: Oh wow, hundreds of millions.
• 1:54
  Speaker 2: Yeah, collectively, it is a staggering global health crisis. Yet
• 1:58
  Speaker 2: when you zoom in on any one specific condition, it
• 2:01
  Speaker 2: impacts only a tiny, tiny fraction of the population. So
• 2:04
  Speaker 2: without a structural government level intervention, the commercial justification for
• 2:09
  Speaker 2: developing those treatments simply does not exist.
• 2:12
  Speaker 1: To really grasp how companies navigate this system, I feel
• 2:16
  Speaker 1: like we first have to look at why the system
• 2:18
  Speaker 1: was built in the first place, which is entirely about
• 2:21
  Speaker 1: fixing that broken equation you just mentioned. Right, Think about
• 2:24
  Speaker 1: it like this. Imagine you are an automotive manufacturer, okay,
• 2:29
  Speaker 1: and you decide to design a custom, state of the
• 2:32
  Speaker 1: art supercar. You pour billions into the R and D
• 2:35
  Speaker 1: wind tunnels, safety testing, custom parts, but your entire global
• 2:41
  Speaker 1: market for this car consists of exactly five buyers.
• 2:45
  Speaker 2: Right. No bank on Earth is going to finance that operation.
• 2:47
  Speaker 1: Not a chance, I mean, unless the government steps in
• 2:50
  Speaker 1: and says, look, society really needs this specific car to exist.
• 2:54
  Speaker 1: If you take the financial risk to build it, we
• 2:56
  Speaker 1: will give you massive tax breaks on your research, and
• 2:58
  Speaker 1: we will legally guarante that nobody else is allowed to
• 3:01
  Speaker 1: sell a car to those five people for the next
• 3:03
  Speaker 1: ten years.
• 3:03
  Speaker 2: That's a great way to.
• 3:04
  Speaker 1: Put it, because without that government granted monopoly and those
• 3:07
  Speaker 1: financial buffers, the car never gets built. It stays a blueprint.
• 3:11
  Speaker 2: That analogy perfectly captures the mechanism behind orphan drug designations.
• 3:16
  Speaker 2: These frameworks, they aren't charity. They are deliberate economic levers
• 3:21
  Speaker 2: designed to rebalance the risk reward ratio for drug sponsors.
• 3:26
  Speaker 1: But reading through the dd REG analysis, a crucial strategic
• 3:29
  Speaker 1: insight really stuck out to me. A pharmaceutical company can't
• 3:32
  Speaker 1: afford to just settle for one government's incentives.
• 3:35
  Speaker 2: No, absolutely, not getting an orphan designation in just the
• 3:39
  Speaker 2: United States or say just the European Union. It leaves
• 3:43
  Speaker 2: vital money and legal protections.
• 3:45
  Speaker 1: On the table because the disease itself doesn't respect borders.
• 3:48
  Speaker 1: I mean, you have patients scattered across the globe, you
• 3:50
  Speaker 1: have clinical trials that have to operate internationally just to
• 3:53
  Speaker 1: find enough participants.
• 3:54
  Speaker 2: Right exactly, and you have patient advocacy groups lobbying worldwide.
• 3:59
  Speaker 2: A developer essentially needs a cross market strategy.
• 4:03
  Speaker 1: So they have to stack these designations.
• 4:05
  Speaker 2: Yes, stacking them across multiple global markets provides extended, overlapping
• 4:09
  Speaker 2: market exclusivity in each jurisdiction. And that is a company's
• 4:13
  Speaker 2: primary revenue protection mechanism. It's their shield, right and beyond
• 4:17
  Speaker 2: the monopoly aspect. It drastically reduces regulatory fees across multiple agencies,
• 4:23
  Speaker 2: which is huge because it preserves early stage capital. But
• 4:27
  Speaker 2: perhaps most importantly, securing these designations signals regulatory seriousness.
• 4:32
  Speaker 1: Meaning it shows they aren't just messing around in a
• 4:34
  Speaker 1: lab somewhere exactly.
• 4:35
  Speaker 2: It tells institutional investors, future pharmaceutical partners, and those patient
• 4:40
  Speaker 2: organizations that independent government scientists have actually looked at your
• 4:44
  Speaker 2: data and deemed your clinical science credible.
• 4:47
  Speaker 1: But here's the foundational puzzle. The definition of what constitutes
• 4:50
  Speaker 1: a rare disease changes depending on where you are on.
• 4:53
  Speaker 2: The map it does. It varies wildly.
• 4:55
  Speaker 1: Like in the United States, to trigger these lucrative incentives,
• 4:58
  Speaker 1: the baseline threshold is that the disease must affect fewer
• 5:01
  Speaker 1: than two hundred thousand patients across the country, But in
• 5:04
  Speaker 1: the European Union the math is entirely different. The disease
• 5:07
  Speaker 1: has to affect fewer than five and ten thousand people.
• 5:10
  Speaker 2: Right, which translates to roughly twenty seven thousand people across
• 5:13
  Speaker 2: the entire EU block.
• 5:14
  Speaker 1: Two hundred thousand versus twenty seven thousand. That is a
• 5:17
  Speaker 1: massive discrepancy.
• 5:18
  Speaker 2: It's huge. A disease could easily be considered rare in
• 5:21
  Speaker 2: the US but fail to meet the threshold in Europe,
• 5:24
  Speaker 2: or vice versa, depending on genetic prevalence, or regional environmental factors.
• 5:29
  Speaker 1: Okay, So, knowing that these economic levers exist, let's look
• 5:33
  Speaker 1: closer at the two biggest regulatory heavyweights in the room,
• 5:37
  Speaker 1: the US Food and Drug Administration the FDA and the
• 5:40
  Speaker 1: European Medicines Agency the EMA, the Big two, right, and
• 5:45
  Speaker 1: reading the source material, it becomes glaringly obvious that despite
• 5:48
  Speaker 1: having the exact same overarching goal getting rare disease drugs
• 5:52
  Speaker 1: to market, their rule books are fundamentally opposed.
• 5:55
  Speaker 2: They really are.
• 5:56
  Speaker 1: So.
• 5:56
  Speaker 2: The US framework originates from the Orphan Drug Act of
• 5:59
  Speaker 2: nineteen eighty three, which essentially serves as the blueprint for
• 6:02
  Speaker 2: the rest.
• 6:02
  Speaker 1: Of the world. They were kind of the pioneers.
• 6:05
  Speaker 2: Very much so, and the incentives they offer are substantial.
• 6:08
  Speaker 2: The crown jewel is seven years of market exclusivity post approval.
• 6:11
  Speaker 2: For seven full years, the FDA will not approve another
• 6:14
  Speaker 2: drug for that exact same disease.
• 6:16
  Speaker 1: And then you have the financial incentives on top of
• 6:18
  Speaker 1: that right.
• 6:19
  Speaker 2: Primarily a tax credit on qualifying clinical trial costs. Now,
• 6:23
  Speaker 2: it was originally fifty percent, and though recent tax legislation
• 6:26
  Speaker 2: reduced it to twenty five percent, it still remains a
• 6:29
  Speaker 2: vital mechanism for recouping your R and D spend.
• 6:32
  Speaker 1: Plus, they waive the PDUFA application fees. And for context
• 6:36
  Speaker 1: for you listening, the Prescription Drug User Fee Act requires
• 6:39
  Speaker 1: companies to pay the FDA to actually review their drug applications.
• 6:42
  Speaker 2: And those aren't cheap.
• 6:43
  Speaker 1: No, Those fees can easily hit three or four million
• 6:47
  Speaker 1: dollars just to submit the paperwork. I mean, for a
• 6:49
  Speaker 1: small biotech startup running on venture capital, getting a three
• 6:52
  Speaker 1: million dollar fee waved. That's the difference between surviving to
• 6:55
  Speaker 1: the next phase or shutting down the company entirely.
• 6:58
  Speaker 2: Absolutely, Plus, developers get enhanced direct access to the agency
• 7:02
  Speaker 2: through a specialized branch called the Office of Orphan Products Development.
• 7:06
  Speaker 2: They essentially act as regulatory shurpis to guide you through
• 7:09
  Speaker 2: the whole process.
• 7:10
  Speaker 1: That's a great deal, But what really caught my eye
• 7:12
  Speaker 1: is their eligibility standard.
• 7:13
  Speaker 2: Ah. Yes, the plausible hypothesis right.
• 7:17
  Speaker 1: To get this designation in the US, a sponsor only
• 7:20
  Speaker 1: needs to demonstrate a plausible hypothesis. And I have to
• 7:24
  Speaker 1: push back on that standard a bit. A plausible hypothesis
• 7:27
  Speaker 1: sounds almost dangerously easy.
• 7:29
  Speaker 2: It is definitely a low bar.
• 7:30
  Speaker 1: It implies you don't need to have finished massive phase
• 7:33
  Speaker 1: three clinical trials or even phase two. You just need
• 7:36
  Speaker 1: a coherent scientific rationale, maybe some published literature and some
• 7:41
  Speaker 1: early animal data, to show that the drug you know,
• 7:44
  Speaker 1: might work.
• 7:44
  Speaker 2: Yeah, that's pretty much it doesn't that.
• 7:46
  Speaker 1: Create a huge junk science problem? Are they just handing
• 7:48
  Speaker 1: out these seven year monopolies to anyone with a promising
• 7:51
  Speaker 1: test tube?
• 7:52
  Speaker 2: Well, it is a deliberately low threshold, designed specifically to
• 7:56
  Speaker 2: cast a really wide net and encourage companies to enter
• 7:59
  Speaker 2: the disease space as early as possible. But to address
• 8:03
  Speaker 2: your junk science concern, that seven year exclusivity is not
• 8:07
  Speaker 2: an impenetrable fortress.
• 8:08
  Speaker 1: Okay, so they can revoke it.
• 8:10
  Speaker 2: Well, the FDA grants the monopoly, but they include a
• 8:14
  Speaker 2: massive caveat. They won't approve a competitors drug for those
• 8:17
  Speaker 2: seven years unless that competitor proves clinical superiority.
• 8:21
  Speaker 1: Clinical superiority meaning the rival company comes in and proves
• 8:25
  Speaker 1: their new drug is safer or more effective, or provides
• 8:29
  Speaker 1: some major contribution to patient care.
• 8:32
  Speaker 2: Precisely, the Diplomeit and Catalyst Pharmaceuticals cases are prime examples
• 8:37
  Speaker 2: of this vulnerability in the real world.
• 8:39
  Speaker 1: What happened there?
• 8:40
  Speaker 2: Basically, a company can spend a billion dollars, cross the
• 8:43
  Speaker 2: finish line, get their seven year monopoly, and then three
• 8:46
  Speaker 2: years later a competitor arrives with a version of the
• 8:49
  Speaker 2: drug that requires say, one pill a day instead of
• 8:53
  Speaker 2: a painful daily injection.
• 8:54
  Speaker 1: Oh wow, and that counts as a major contribution to
• 8:57
  Speaker 1: patient care.
• 8:58
  Speaker 2: Yes, the FDA will break the original exclusivity and let
• 9:02
  Speaker 2: that competitor into the market. It proves that market exclusivity
• 9:05
  Speaker 2: in the US is much more fragile than developers often assume.
• 9:08
  Speaker 1: So the US strategy is to offer this early, low
• 9:11
  Speaker 1: barrier entry, but with a fragile back end protection exactly. Now,
• 9:15
  Speaker 1: if we look at the European Medicines Agency handled through
• 9:17
  Speaker 1: their Committee for Organ Medicinal Products, the strategy is entirely inverted.
• 9:22
  Speaker 2: Yeah, the European incentive package is arguably much more robust.
• 9:26
  Speaker 2: Sponsors receive ten years of market exclusivity post approval, and
• 9:30
  Speaker 2: that can actually be extended by two additional years if
• 9:33
  Speaker 2: they comply with pediatric development plans.
• 9:35
  Speaker 1: Twelve years is a massive monopoly.
• 9:37
  Speaker 2: It's huge. They also receive significant fee reductions and protocol assistance,
• 9:43
  Speaker 2: but crucially they become eligible for the mandatory centralized procedure, which.
• 9:47
  Speaker 1: Means they don't have to go country by country.
• 9:49
  Speaker 2: Right, instead of navigating the health ministries and pricing boards
• 9:53
  Speaker 2: of twenty seven different European countries individually, a developer gets
• 9:56
  Speaker 2: one unified marketing authorization for the entire e block.
• 10:01
  Speaker 1: But getting that EU designation requires clearing a massive hurdle because,
• 10:05
  Speaker 1: unlike the US, the EU does not accept a simple
• 10:08
  Speaker 1: plausible hypothesis.
• 10:10
  Speaker 2: No, not at all. They demand a significant benefit test.
• 10:13
  Speaker 1: Right. You have to prove the condition is life threatening
• 10:15
  Speaker 1: or chronically and seriously debilitating. You can't just bring them
• 10:19
  Speaker 1: a rare cosmetic skin condition. It has to have a
• 10:22
  Speaker 1: severe functional impact on the patient.
• 10:24
  Speaker 2: Furthermore, if there is already any approved treatment on the
• 10:27
  Speaker 2: market for that rare disease, the developer has to prove
• 10:30
  Speaker 2: their new drug offers a clinically relevant advantage from day one.
• 10:34
  Speaker 1: So you can't just say, hey, ours works two exactly.
• 10:37
  Speaker 2: A sponsor cannot simply demonstrate that their drug also works.
• 10:41
  Speaker 2: They must prove it works demonstrably better than the current
• 10:44
  Speaker 2: standard of care.
• 10:45
  Speaker 1: Let's consider the math on a global scale for a second.
• 10:48
  Speaker 1: What happens if a disease affects, say, fifteen thousand people globally. Technically,
• 10:54
  Speaker 1: it falls well below the two hundred thousand threshold in
• 10:57
  Speaker 1: the US and it falls below the twenty seven thousand
• 11:00
  Speaker 1: threshold in the EU.
• 11:01
  Speaker 2: Right, so it qualifies for both based on prevalence.
• 11:03
  Speaker 1: But because the FDA wants early plausible hypotheses and the
• 11:07
  Speaker 1: EMA demands rigorous proof of significant benefit, a company can't
• 11:11
  Speaker 1: just build one master binder of data and mail it
• 11:14
  Speaker 1: to both agencies, can they?
• 11:15
  Speaker 2: They absolutely cannot. The US offers an early gateway, allowing
• 11:19
  Speaker 2: developers to secure designation before they even begin human trials,
• 11:23
  Speaker 2: but the EU requires a much heavier burden.
• 11:25
  Speaker 1: Of proof, which means waiting.
• 11:27
  Speaker 2: Yeah, it often necessitates mature phase two or Phase three
• 11:30
  Speaker 2: clinical data to definitively prove that significant benefit. This forces
• 11:35
  Speaker 2: a staggered, highly coordinated cross market strategy, and.
• 11:39
  Speaker 1: The rules in Europe might be shifting even further. Right,
• 11:42
  Speaker 1: I read that the European Commission is currently navigating an
• 11:45
  Speaker 1: orphan regulation reform expected to roll out through twenty twenty six.
• 11:49
  Speaker 2: Yes, that's a huge shift on the horizon. This reform
• 11:52
  Speaker 2: proposes modifying that ten year market exclusivity period, tweaking the
• 11:56
  Speaker 2: exact definition of significant benefit and targeting the financial incentives
• 12:01
  Speaker 2: much more strictly toward diseases with absolutely zero existing treatments.
• 12:06
  Speaker 1: Wow, that could alter the entire commercial logic for a
• 12:09
  Speaker 1: drug currently sitting midway through its clinical trial.
• 12:11
  Speaker 2: Without a doubt. It's a very precarious time and because
• 12:14
  Speaker 2: the US and EU markets require such distinct approaches in
• 12:17
  Speaker 2: heavy clinical data, the dd rank strategic analysis points out
• 12:21
  Speaker 2: that savvy developers do not confine their focus just to
• 12:23
  Speaker 2: the West.
• 12:24
  Speaker 1: They look for other options.
• 12:25
  Speaker 2: Right to find the resources and early phase advantages necessary
• 12:28
  Speaker 2: to conquer the US and Europe, they look to the Pacific.
• 12:31
  Speaker 1: Which brings US to Japan and Australia. I think the
• 12:35
  Speaker 1: instinct for a lot of people might be to view
• 12:37
  Speaker 1: these as secondary, smaller markets to hit after the drug
• 12:40
  Speaker 1: is already successful.
• 12:41
  Speaker 2: Sure, that's the traditional view, but.
• 12:43
  Speaker 1: In this regulatory chess game, they act as critical launch pads.
• 12:47
  Speaker 1: Let's examine Japan's Pharmaceuticals and Medical Devices Agency the PMDA.
• 12:51
  Speaker 1: Their threshold for a rare disease is fewer than fifty
• 12:54
  Speaker 1: thousand patients domestically, and.
• 12:56
  Speaker 2: The incentives there are incredibly robust. You get priority consultations
• 13:00
  Speaker 2: up to ten years of exclusivity and actual direct financial
• 13:04
  Speaker 2: subsidies for development costs from the Japanese government through aimed.
• 13:08
  Speaker 1: Direct subsidies are incredible. But the true strategic value in
• 13:12
  Speaker 1: Japan seems to be a specific regulatory synergy.
• 13:15
  Speaker 2: Yes, Japan utilizes a priority review pathway called the Sakigate designation.
• 13:21
  Speaker 2: It's intended for highly innovative medicines addressing serious unmet needs,
• 13:25
  Speaker 2: and it's.
• 13:25
  Speaker 1: Basically a rolling review process right exactly.
• 13:27
  Speaker 2: Instead of a company waiting years to compile one massive
• 13:30
  Speaker 2: final submission, the agency reviews the data piece by piece
• 13:34
  Speaker 2: as it emerges from.
• 13:35
  Speaker 1: The lab, shaving years off the development timeline.
• 13:38
  Speaker 2: Years. Combining the saka Gate designation with an Orphan designation
• 13:42
  Speaker 2: maximizes the support package. A developer gains access to dedicated
• 13:46
  Speaker 2: consultation channels, prior review mechanisms, and vastly accelerated timelines.
• 13:51
  Speaker 1: And I imagine this infrastructure is particularly crucial for diseases
• 13:56
  Speaker 1: prevalent in East Asian populations, very much so.
• 13:59
  Speaker 2: Engaging early in Japan unlocks a regulatory environment that drastically
• 14:03
  Speaker 2: reduces regional development costs, all while generating world class clinical data.
• 14:09
  Speaker 1: Okay, then we have Australia's Therapeutic Goods Administration the TGA.
• 14:13
  Speaker 1: Their patient threshold is incredibly strict. The condition must affect
• 14:16
  Speaker 1: fewer than two thousand patients.
• 14:18
  Speaker 2: In Australia, which is a timy number.
• 14:20
  Speaker 1: Very tiny, but meeting that unlocks priority review and fee reductions. However,
• 14:25
  Speaker 1: reading this deep dive into the d dragreg materials, the
• 14:27
  Speaker 1: real strategic superpower of Australia isn't the orphan designation itself.
• 14:32
  Speaker 2: No, it's the clinical trial infrastructure.
• 14:34
  Speaker 1: Yes, specifically the Clinical Trial Notification Scheme or CTN paired
• 14:38
  Speaker 1: with their research and development tax incentive.
• 14:40
  Speaker 2: It's a brilliant setup. Early clinical trials, just proving the
• 14:43
  Speaker 2: drug doesn't harm humans and finding the right dose are
• 14:46
  Speaker 2: phenomenally expensive and administratively burdensome.
• 14:49
  Speaker 1: In the US, a company has to file an investigational
• 14:52
  Speaker 1: new Drug application and wait for the FDA to review
• 14:55
  Speaker 1: it before they can even touch a single.
• 14:57
  Speaker 2: Patient right, which takes months of agon back and forth.
• 15:01
  Speaker 2: But in Australia, under the CTN scheme, a developer essentially
• 15:06
  Speaker 2: just notifies the government that they are starting a trial,
• 15:08
  Speaker 2: just a notification basically, yeah, as long as a local
• 15:11
  Speaker 2: hospital's ethics committee approves the study, the developer bypasses the heavy,
• 15:17
  Speaker 2: months long upfront regulatory review. They can initiate the trial
• 15:20
  Speaker 2: almost immediately.
• 15:21
  Speaker 1: That is insane.
• 15:23
  Speaker 2: Plus the Australian government offers a massive cash refund on
• 15:26
  Speaker 2: R and D spent in the country. Australia operates as
• 15:29
  Speaker 2: the ultimate incubator.
• 15:31
  Speaker 1: It's a sandbox. I mean, why fight the immediate, expensive,
• 15:34
  Speaker 1: uphill battle trying to prove significant benefit in the EU
• 15:37
  Speaker 1: when a developer can fly to Australia, use their generous
• 15:41
  Speaker 1: tax incentives and a lightning fast CTN scheme to run
• 15:44
  Speaker 1: early phase trials, affordably.
• 15:46
  Speaker 2: Generate all that vital clinical.
• 15:47
  Speaker 1: Data exactly and then take that solid, proven data back
• 15:51
  Speaker 1: to the FDA and the EMA.
• 15:53
  Speaker 2: It is a masterclass in regulatory sequencing. It highlights how
• 15:57
  Speaker 2: these smaller markets are not just an afterthought, they are
• 16:00
  Speaker 2: operational tools. Developers leverage the supportive environment and tax structures
• 16:05
  Speaker 2: of a place like Australia to physically fund and prove
• 16:08
  Speaker 2: the underlying science that the larger, stricter markets demand.
• 16:12
  Speaker 1: So we've established the disparate rules across these four major regions.
• 16:16
  Speaker 1: You've got the early gateway of the US, the strict
• 16:19
  Speaker 1: data hurdle of the EU, the innovative synergy in Japan,
• 16:22
  Speaker 1: and the incubator sandbox of Australia.
• 16:24
  Speaker 2: Right.
• 16:24
  Speaker 1: But coordinating this globally has got to be immensely difficult.
• 16:28
  Speaker 1: It sounds like a game of three D chess, where
• 16:30
  Speaker 1: a move in one jurisdiction can easily trigger a catastrophic
• 16:32
  Speaker 1: penalty in another.
• 16:33
  Speaker 2: Oh it is incredibly precarious. The primary coordination challenge lies
• 16:37
  Speaker 2: in prevalence.
• 16:38
  Speaker 1: Documentation counting the patients, right.
• 16:40
  Speaker 2: The FDA demands US patient numbers, the EMA demands EU numbers.
• 16:44
  Speaker 2: Japan and Australia demand their own domestic figures. But for
• 16:47
  Speaker 2: an ultra rare condition, robust epidemiological data rarely exists for
• 16:52
  Speaker 2: every specific.
• 16:53
  Speaker 1: Zip code, right, So developers are forced to rely on
• 16:56
  Speaker 1: fragmented academic literature, scattered patient registry, maybe some expert opinions.
• 17:01
  Speaker 2: And the danger is that they have to repackage that
• 17:03
  Speaker 2: exact same underlying global data to fit each distinct local threshold.
• 17:08
  Speaker 1: Oh I. See if a regulatory agency notices inconsistencies, like
• 17:12
  Speaker 1: if a company's mathematical methodology for counting patients looks entirely
• 17:16
  Speaker 1: different in Europe than it does in the US, they
• 17:18
  Speaker 1: just lose all credibility instantly.
• 17:20
  Speaker 2: Navigating this requires a unified global strategy, which DDRAG visualizes
• 17:25
  Speaker 2: as a five step life cycle.
• 17:26
  Speaker 1: Okay, walk me through that.
• 17:27
  Speaker 2: First comes the epidemiological analysis, basically defining where your data
• 17:31
  Speaker 2: gaps are. Second is threshold mapping. You physically compare the
• 17:35
  Speaker 2: prevalence data against the two hundred thousand US limit or
• 17:38
  Speaker 2: the twenty seven thousand EU limit to determine if the
• 17:41
  Speaker 2: commercial benefit even justifies the cost of filing makes sense.
• 17:45
  Speaker 1: What's step three?
• 17:46
  Speaker 2: Third is aligning the scientific rationale, ensuring you have a
• 17:49
  Speaker 2: consistent global story about how the disease actually works. Fourth
• 17:52
  Speaker 2: is mastering the sequence.
• 17:53
  Speaker 1: In timing, like we talked about, hitting the FTA early,
• 17:56
  Speaker 1: utilizing Australia for data generation, and approaching the EMA later
• 18:00
  Speaker 1: when the data matures exactly.
• 18:03
  Speaker 2: And finally step five, developers must manage post designation maintenance,
• 18:07
  Speaker 2: tracking annual updates in shifting prevalence numbers.
• 18:11
  Speaker 1: I want to zero in on step three, the scientific
• 18:13
  Speaker 1: rationale alignment, because the strategy framework highlights a terrifying vulnerability
• 18:18
  Speaker 1: regarding what they call indication language.
• 18:20
  Speaker 2: Yes, the TYPEO trap, the.
• 18:22
  Speaker 1: Typotrap, so the FDA and the EMA interpret the phrase
• 18:26
  Speaker 1: same indication differently. I want to construct a hypothetical here
• 18:29
  Speaker 1: to see if I understand this. Let's say a developer
• 18:32
  Speaker 1: creates a drug for a rare nerve condition to maximize
• 18:36
  Speaker 1: their market under the FDA's two hundred thousand patient cap.
• 18:40
  Speaker 1: They apply in the US using very broad language they
• 18:43
  Speaker 1: call it simply peripheral neuropathy. But in Europe, because they
• 18:47
  Speaker 1: have to prove that strict significant benefit over existing therapies,
• 18:51
  Speaker 1: they apply using highly narrowed language, they call it severe
• 18:54
  Speaker 1: refractory peripheral neuropathy in adults. Does that phrasing mismatch actually.
• 18:58
  Speaker 2: Matter immensely because the agencies define the indication based on
• 19:04
  Speaker 2: the exact phrasing in the application. Sloppy cross market language
• 19:09
  Speaker 2: artificially creates a legal loophole. Wow in your hypothetical. By
• 19:13
  Speaker 2: defining the disease narrowly in Europe, the developer has left
• 19:17
  Speaker 2: the back door wide open. A rival company can observe
• 19:20
  Speaker 2: that narrow EU language, swoop in and apply for their
• 19:24
  Speaker 2: own orphan designation for the pediatric version of the disease
• 19:27
  Speaker 2: or the moderate version.
• 19:28
  Speaker 1: So the original developer has legally forfeited a massive segment
• 19:32
  Speaker 1: of their potential monopoly simply because they altered a few
• 19:35
  Speaker 1: adjectives between applications.
• 19:37
  Speaker 2: Yes, a unified, globally consistent scientific narrative isn't just about
• 19:42
  Speaker 2: sounding intelligent across borders. The literal phrasing of the application
• 19:45
  Speaker 2: acts as a legal shield to protect the monopoly. The
• 19:48
  Speaker 2: language used in these jurisdictions application must be flawlessly coordinated
• 19:52
  Speaker 2: with the global clinical development plan from day one, because
• 19:55
  Speaker 2: a single misaligned sentence can erode years of exclusivity.
• 19:59
  Speaker 1: Bringing this all back to you, the listener, if you
• 20:02
  Speaker 1: have ever wondered why certain rare diseases suddenly experience a
• 20:05
  Speaker 1: rush of cutting edge treatments, Why you see headlines about
• 20:09
  Speaker 1: a miracle drug for one obscure condition while another rare
• 20:13
  Speaker 1: disease continues to linger in the shadows without any treatments
• 20:15
  Speaker 1: at all. It is not solely about the underlying biology.
• 20:19
  Speaker 2: No, the science is paramount, certainly, but it's not the
• 20:22
  Speaker 2: whole story.
• 20:22
  Speaker 1: It is equally about this underlying regulatory scaffolding. The medicines
• 20:27
  Speaker 1: that actually survive the decade long journey to reach the
• 20:30
  Speaker 1: pharmacy shelves are overwhelmingly the ones championed by development teams
• 20:34
  Speaker 1: who didn't just understand test tubes, but who knew how
• 20:37
  Speaker 1: to play this complex, high stakes global regulatory chess game.
• 20:41
  Speaker 2: It requires knowing precisely when to leverage Australia's tax incentives
• 20:45
  Speaker 2: to fund early data, when to utilize the FDA's low
• 20:48
  Speaker 2: barrier gateway to attract initial venture capital, and how to
• 20:51
  Speaker 2: build a clinical trial robust enough to survive the EUS
• 20:54
  Speaker 2: punishing significant benefit test.
• 20:56
  Speaker 1: But looking forward, this entire global infrastructure relies on on
• 21:00
  Speaker 1: strict numerical prevalence thresholds, the two hundred thousand limit in
• 21:04
  Speaker 1: the US the twenty seven thousand limit in the EU.
• 21:08
  Speaker 1: The entire system is based on counting.
• 21:10
  Speaker 2: Patients, which introduces a really profound complication. As medical technology evolves,
• 21:16
  Speaker 2: as our understanding of the human geno improves, we are
• 21:19
  Speaker 2: becoming exceptionally skilled at identifying unique genetic markers. We are
• 21:23
  Speaker 2: no longer looking at broad, monolithic diseases. Conditions that the
• 21:27
  Speaker 2: medical community used to consider one large disease like breast
• 21:30
  Speaker 2: cancer or cystic fibrosis are aggressively being sliced into smaller,
• 21:35
  Speaker 2: highly specific genetic subcategories.
• 21:37
  Speaker 1: So what used to be one disease affecting a million
• 21:40
  Speaker 1: people is now recognized as fifty different diseases, each affecting
• 21:43
  Speaker 1: twenty thousand people exactly.
• 21:45
  Speaker 2: So here's something to think about. If every major disease
• 21:47
  Speaker 2: is eventually fragmented into dozens of unique, ultra rare genetic disorders,
• 21:52
  Speaker 2: will the exception become the rule?
• 21:53
  Speaker 1: Wow?
• 21:54
  Speaker 2: As precision medicine advances and diseases are slight, thinner and thinner,
• 21:57
  Speaker 2: could every new drug one day legally qualify as an
• 22:00
  Speaker 2: orphan drug?
• 22:01
  Speaker 1: That is a wild thought to leave off on. If
• 22:03
  Speaker 1: everyone is rare, is anyone rare, We'll leave you to
• 22:06
  Speaker 1: them all that over. Thanks for joining us for this
• 22:09
  Speaker 1: deep dive